Markets:

Overview

News

Currencies

International

Treasuries

AbbVie (NY:ABBV)

220.76 -8.55 (-3.73%)

Streaming Delayed Price Updated: 3:39 PM EST, Jan 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9

...

91 92 Next >

Top S&P500 movers in Monday's session ↗

Today 15:05 EST

Via Chartmill

Flu Season's Here—This Dividend-Payer Controls the Shot Market ↗

Today 14:38 EST

Via MarketBeat

Topics Artificial Intelligence Death

Uncover the latest developments among S&P500 stocks in today's session. ↗

Today 12:35 EST

Via Chartmill

26 Top Dividend Stocks to Buy and Hold in 2026 ↗

Today 4:05 EST

Another year, another long list of great dividend stocks.

Via The Motley Fool

Topics Intellectual Property

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment ↗

Today 3:40 EST

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

Via Stocktwits

Take Warren Buffett's Advice: Don't Buy Any Stock in 2026 Unless It Passes This Test ↗

January 04, 2026

Buffett is no longer at the helm of Berkshire Hathaway. But his investing wisdom remains relevant.

Via The Motley Fool

Buying This Healthcare Stock Could Make You a Millionaire Retiree ↗

January 03, 2026

It won't happen overnight, but patience will be rewarded.

Via The Motley Fool

Topics Intellectual Property Retirement

The Evolution of a Healthcare Giant: Abbott Laboratories (ABT) 2026 Stock Feature

January 01, 2026

As of today, January 1, 2026, Abbott Laboratories (NYSE: ABT) stands as one of the most resilient and strategically diversified giants in the global healthcare landscape. While the broader market has...

Via PredictStreet

Topics Economy Lawsuit World Trade

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

Via MarketMinute

Topics Economy Intellectual Property Law Enforcement

The Great Rebalancing: As Consumer Confidence Falters, Investors Retreat to the Safety of Large-Cap Value

December 31, 2025

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

AbbVie (ABBV): Buy, Sell, or Hold Post Q3 Earnings?

December 30, 2025

AbbVie has had an impressive run over the past six months as its shares have beaten the S&P 500 by 12.4%. The stock now trades at $229.70, marking a 23.7% gain. This performance may have investors...

Via StockStory

Topics Stocks Supply Chain

IGSB vs VCSH: Two Approaches to Short-Term Investment-Grade Credit ↗

December 30, 2025

Both ETFs target short-term investment-grade bonds, but their construction determines how visible credit risk becomes when spreads move.

Via The Motley Fool

Topics Bonds ETFs

3 No-Brainer Dividend Stocks to Buy Right Now ↗

December 30, 2025

You don't need to settle for an average dividend yield.

Via The Motley Fool

Topics ETFs Retirement

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Why a New $3 Million Bet on Pathward Stock Signals Confidence in a Bank Posting $7.87 EPS ↗

December 28, 2025

After a year of steady execution and profitability, Pathward is perhaps starting to look less like a niche lender and more like a quietly scalable earnings machine.

Via The Motley Fool

Is AbbVie a Buy, Sell, or Hold in 2026? ↗

December 27, 2025

It is wrapping up another great year, and there is no sign of a slowdown.

Via The Motley Fool

Topics Intellectual Property

The Best Stocks to Invest $50,000 in Right Now ↗

December 27, 2025

If you're investing for the long run, there are a myriad of companies begging to be bought.

Via The Motley Fool

Topics Artificial Intelligence

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Via PredictStreet

Topics Artificial Intelligence Economy Intellectual Property

Top 5 US Healthcare Stocks By Market Value ↗

December 24, 2025

Weight-loss drugs, drug-pricing reforms, and legal challenges have reshaped the U.S. healthcare landscape in 2025.

Via Stocktwits

The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave

December 23, 2025

As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results...

Via MarketMinute

Topics Intellectual Property

Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever ↗

December 22, 2025

Investors can expect steady dividend returns with these stocks.

Via The Motley Fool

Topics Intellectual Property

3 Dividend Growth Stocks Analysts Are Upgrading for 2026 ↗

December 21, 2025

Via MarketBeat

AbbVie, Merck, Other Top Drugmakers To Lower Prices Of US Drugs In MFN Deal With Trump Administration: Report ↗

December 19, 2025

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

Via Stocktwits

Topics Economy Government

This Is the 2nd Priciest Stock Market in 155 Years, Which Makes This High-Yield ETF a Genius Buy for 2026 ↗

December 19, 2025

This top-shelf exchange-traded fund (ETF) checks all the right boxes for income- and value-seeking investors.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Want $10,000 in Passive Income? This Vanguard ETF Could Be Your Ticket to Making It Happen. ↗

December 18, 2025

Investors would need to have over $330,000 invested in this Vanguard dividend ETF.

Via The Motley Fool

Topics ETFs Stocks

Is AbbVie a Millionaire Maker? ↗

December 18, 2025

AbbVie's third-quarter earnings were disappointing, but the company raised its full-year guidance and increased the dividend.

Via The Motley Fool

Topics Intellectual Property

Worried About the Stock Market in 2026? These 3 Stocks Did Well During the Last Bear Market. ↗

December 18, 2025

The stocks listed here were all up more than 19% in 2022, while the S&P 500 crashed.

Via The Motley Fool

Topics Intellectual Property Stocks

The Yield Search: Why Retirees are Swapping Growth for Defense in a Shifting 2025 Market

December 18, 2025

As of December 18, 2025, the financial landscape is undergoing a significant transformation, forcing retirees to reconsider their high-octane growth strategies in favor of more stable,...

Via MarketMinute

Topics Artificial Intelligence Bonds ETFs

Want Decades of Passive Income? Buy This ETF and Hold It Forever. ↗

December 17, 2025

Can one ETF deliver decades of dividend income? This unique high-quality yield generator deserves a spot on your watchlist.

Via The Motley Fool

Topics ETFs Stocks

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Via Stocktwits

Topics Government World Trade

< Previous 1 2 3 4 5 6 7 8 9

...

91 92 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.